

## 2022 MX-C Intended Responses

### ANTIBODY SPECIFICITIES BY FLOW

MX-13P		MX-14P	
Class I Results	Class II Results	Class I Results	Class II Results
A2, A69, A68, A24, A23, B57, B58, A36, C17, A3, B51, B78, A29, A33	Negative	B7, B73, B67, B42, B81, B27, B55, B56, B82, B54, B48, B60, B61, A66, B13, C1, C14, B47, C17, C2	DR15, DQ6, DQ5, DR16, DR51, DR7, DQ4, DR103, DR1, DR9
MX-15P		MX-16P	
Class I Results	Class II Results	Class I Results	Class II Results
B18, B64, C5, B65, B8, B78, B54, A33, B39, B38, A34, B51, A69, B55, B73, A68, B42, A66, B59, B37, B67, B75, A25, B77, B52, B41, B53, B35, A26	DR1, DR103, DR51, DR10, DR9, DR12	Negative	Negative

CDC- complement-dependent cytotoxicity antibody specificities are no longer a reportable method due to inadequate group size.

### CROSSMATCH RESULTS

MX-13P (1st Set)		
Method	Against MX-17C	Against MX-18C
Direct Cytotoxicity	T and B - both POSITIVE	T and B - both POSITIVE
Flow	T and B - both POSITIVE	T and B - both POSITIVE
MX-14P (2nd Set)		
Method	Against MX-17C	Against MX-18C
Direct Cytotoxicity	T - NEGATIVE B - POSITIVE	T and B - both POSITIVE
Flow	T - NEGATIVE B - POSITIVE	T and B - both POSITIVE
MX-15P (3rd Set)		
Method	Against MX-17C	Against MX-18C
Direct Cytotoxicity	T and B - both POSITIVE	T and B - both NEGATIVE
Flow	T and B - both POSITIVE	T and B - both NEGATIVE
MX-16P (4th Set)		
Method	Against MX-17C	Against MX-18C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE